PULMATRIX INC (PULM) Stock Overview
USA - NASDAQ:PULM - US74584P3010 - Common Stock
PULM Key Statistics, Chart & Performance
The current stock price of PULM is 4.84 USD. In the past month the price increased by 9.26%. In the past year, price increased by 139.62%.
PULM Latest News, Press Relases and Analysis
PULM Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 51.11 | 781.26B | ||
| JNJ | JOHNSON & JOHNSON | 18.34 | 458.55B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.76 | 258.24B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 14.73 | 252.36B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 13.65 | 235.32B | ||
| MRK | MERCK & CO. INC. | 11.36 | 218.53B | ||
| PFE | PFIZER INC | 7.3 | 140.77B | ||
| SNY | SANOFI-ADR | 14.46 | 125.85B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.51 | 89.21B | ||
| GSK | GSK PLC-SPON ADR | 9.67 | 86.97B | ||
| ZTS | ZOETIS INC | 23.46 | 64.68B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 50.04 | 44.25B |
Related stock screener links
About PULM
Company Profile
Pulmatrix, Inc. is a clinical stage biotechnology company, which engages in the development and discovery of novel inhaled therapeutics products. The company is headquartered in Framingham, Massachusetts and currently employs 2 full-time employees. The company went IPO on 2014-03-21. The firm is focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with unmet medical needs using its patented iSPERSE technology. The Company’s proprietary product pipeline includes treatments for central nervous system (CNS) disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease (COPD) and allergic bronchopulmonary aspergillosis (ABPA). Pulmatrix’s product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE, which seeks to enhance therapeutic delivery to the lungs by optimizing pharmacokinetics and reducing systemic side effects to improve patient outcomes. iSPERSE is a proprietary technology that allows a broad range of drugs to be formulated as small, dense, and dispersible particles for efficient drug delivery and deep penetration into the lungs.
Company Info
PULMATRIX INC
945 Concord Street, Suite 1217
Framingham MASSACHUSETTS 02421 US
CEO: Teofilo Raad
Employees: 2
Phone: 18883554440
PULMATRIX INC / PULM FAQ
Can you describe the business of PULMATRIX INC?
Pulmatrix, Inc. is a clinical stage biotechnology company, which engages in the development and discovery of novel inhaled therapeutics products. The company is headquartered in Framingham, Massachusetts and currently employs 2 full-time employees. The company went IPO on 2014-03-21. The firm is focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with unmet medical needs using its patented iSPERSE technology. The Company’s proprietary product pipeline includes treatments for central nervous system (CNS) disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease (COPD) and allergic bronchopulmonary aspergillosis (ABPA). Pulmatrix’s product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE, which seeks to enhance therapeutic delivery to the lungs by optimizing pharmacokinetics and reducing systemic side effects to improve patient outcomes. iSPERSE is a proprietary technology that allows a broad range of drugs to be formulated as small, dense, and dispersible particles for efficient drug delivery and deep penetration into the lungs.
What is the stock price of PULMATRIX INC today?
The current stock price of PULM is 4.84 USD. The price decreased by -0.21% in the last trading session.
What is the dividend status of PULMATRIX INC?
PULM does not pay a dividend.
How is the ChartMill rating for PULMATRIX INC?
PULM has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Is PULMATRIX INC (PULM) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on PULM.
Can you provide the market cap for PULMATRIX INC?
PULMATRIX INC (PULM) has a market capitalization of 17.67M USD. This makes PULM a Nano Cap stock.
What is the Short Interest ratio of PULMATRIX INC (PULM) stock?
The outstanding short interest for PULMATRIX INC (PULM) is 0.16% of its float.
PULM Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to PULM. When comparing the yearly performance of all stocks, PULM is one of the better performing stocks in the market, outperforming 93.54% of all stocks.
PULM Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to PULM. PULM has a great financial health rating, but its profitability evaluates not so good.
PULM Financial Highlights
Over the last trailing twelve months PULM reported a non-GAAP Earnings per Share(EPS) of -1.7. The EPS increased by 35.59% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -124.85% | ||
| ROE | -131.42% | ||
| Debt/Equity | 0 |
PULM Forecast & Estimates
For the next year, analysts expect an EPS growth of -10% and a revenue growth 1% for PULM